Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Akcea Therapeutics Inc. AKCA

Healthcare Biotechnology
Akcea Therapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It is advancing a mature pipeline of novel drugs with the potential to treat multiple diseases. The company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are... see more

Recent & Breaking News (NDAQ:AKCA)

Akcea and Ionis Receive Positive EU CHMP Opinion for WAYLIVRATM (volanesorsen)

GlobeNewswire March 1, 2019

Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2018

GlobeNewswire February 26, 2019

AKCEA-APO(a)-LRx Advances as Leading Pharmaceutical Company Exercises Option to License

GlobeNewswire February 25, 2019

Akcea Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire February 20, 2019

Akcea Therapeutics to Hold Fourth Quarter and Full Year 2018 Financial Results Webcast

GlobeNewswire February 13, 2019

Consolidated Research: 2018 Summary Expectations for TD Ameritrade Holding, Supernus Pharmaceuticals, Akcea Therapeutics, Dell Technologies, iRobot, and Pegasystems — Fundamental Analysis, Key Performance Indications

GlobeNewswire December 6, 2018

Akcea Announces Upcoming Data Presentations at the 2018 American Society of Hematology Annual Meeting

GlobeNewswire November 29, 2018

Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions

GlobeNewswire November 12, 2018

Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions

GlobeNewswire November 8, 2018

Akcea Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire November 6, 2018

Akcea Reports Financial Results and Highlights for Third Quarter 2018

GlobeNewswire November 5, 2018

Akcea Recognizes First Global Familial Chylomicronemia Syndrome (FCS) Awareness Day

GlobeNewswire November 2, 2018

Akcea Therapeutics to Hold Third Quarter 2018 Financial Results Webcast

GlobeNewswire October 22, 2018

Akcea Announces Changes to Board of Directors

GlobeNewswire October 8, 2018

Akcea Announces Its Access and Distribution Strategy for TEGSEDI™ (inotersen)

GlobeNewswire October 5, 2018

Akcea and Ionis Receive FDA Approval of TEGSEDI™ (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

GlobeNewswire October 5, 2018

Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen injection) in Canada

GlobeNewswire October 4, 2018

Akcea and Ionis Report Positive Data from Phase 2 Study of AKCEA-APO(a)-LRx

GlobeNewswire September 24, 2018

Akcea Therapeutics to Present at the Wells Fargo Healthcare Conference

GlobeNewswire August 29, 2018

Akcea and Ionis Receive Complete Response Letter for WAYLIVRA from FDA

GlobeNewswire August 27, 2018